Delivering Precision Therapy

Our patented technology is designed to be tailored to a wide variety of drugs and therapeutic indications. In addition to our lead drug candidate (EP-104IAR), Eupraxia is currently developing an extended-release post-surgical anesthetic (EP-105) and antibiotic (EP-201). Eupraxia hopes to add 1-2 additional candidates to our pipeline within the next year, including an internally developed oncology product.

Pipeline Graphic